The stock of Boston Scientific Corp. (BSX) has gone up by 8.67% for the week, with a 6.63% rise in the past month and a 19.70% rise in the past quarter. The volatility ratio for the week is 1.87%, and the volatility levels for the past 30 days are 1.53% for BSX.. The simple moving average for the past 20 days is 6.60% for BSX’s stock, with a 26.41% simple moving average for the past 200 days.
Is It Worth Investing in Boston Scientific Corp. (NYSE: BSX) Right Now?
Boston Scientific Corp. (NYSE: BSX) has a price-to-earnings ratio that is above its average at 61.13x. The stock has a 36-month beta value of 0.76. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 10 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BSX is 1.46B, and at present, short sellers hold a 0.90% of that float. On April 29, 2024, the average trading volume of BSX was 6.51M shares.
BSX) stock’s latest price update
The stock price of Boston Scientific Corp. (NYSE: BSX) has dropped by -0.12 compared to previous close of 73.26. Despite this, the company has seen a gain of 8.67% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-26 that Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Mizuho repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Mizuho is $80 based on the research report published on February 01, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see BSX reach a price target of $59. The rating they have provided for BSX stocks is “Outperform” according to the report published on July 19th, 2023.
CL King gave a rating of “Buy” to BSX, setting the target price at $64 in the report published on June 30th of the previous year.
BSX Trading at 8.19% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.64% of loss for the given period.
Volatility was left at 1.53%, however, over the last 30 days, the volatility rate increased by 1.87%, as shares surge +6.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.95% upper at present.
During the last 5 trading sessions, BSX rose by +8.67%, which changed the moving average for the period of 200-days by +39.48% in comparison to the 20-day moving average, which settled at $68.88. In addition, Boston Scientific Corp. saw 26.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Sorenson John Bradley, who sale 16,351 shares at the price of $69.30 back on Apr 01 ’24. After this action, Sorenson John Bradley now owns 50,638 shares of Boston Scientific Corp., valued at $1,133,069 using the latest closing price.
Carruthers Wendy, the EVP, Human Resources of Boston Scientific Corp., sale 6,983 shares at $68.42 during a trade that took place back on Apr 01 ’24, which means that Carruthers Wendy is holding 51,068 shares at $477,777 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.69 for the gross margin
The net margin for Boston Scientific Corp. stands at 0.12. The total capital return value is set at 0.08. Equity return is now at value 8.64, with 4.71 for asset returns.
Based on Boston Scientific Corp. (BSX), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is 9.2.
Currently, EBITDA for the company is 3.62 billion with net debt to EBITDA at 2.61. When we switch over and look at the enterprise to sales, we see a ratio of 7.9. The receivables turnover for the company is 6.6for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.32.
Conclusion
To sum up, Boston Scientific Corp. (BSX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
